"Cyclin-Dependent Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Protein kinases that control cell cycle progression in all eukaryotes and require physical association with CYCLINS to achieve full enzymatic activity. Cyclin-dependent kinases are regulated by phosphorylation and dephosphorylation events.
| Descriptor ID |
D018844
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.646.500 D12.644.360.250 D12.776.167.200 D12.776.476.250
|
| Concept/Terms |
Cyclin-Dependent Kinases- Cyclin-Dependent Kinases
- Cyclin Dependent Kinases
- Cyclin-Dependent Protein Kinases
- Cyclin Dependent Protein Kinases
- cdk Proteins
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinases".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinases".
This graph shows the total number of publications written about "Cyclin-Dependent Kinases" by people in this website by year, and whether "Cyclin-Dependent Kinases" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 5 | 3 | 8 |
| 1996 | 6 | 4 | 10 |
| 1997 | 10 | 4 | 14 |
| 1998 | 9 | 9 | 18 |
| 1999 | 9 | 9 | 18 |
| 2000 | 9 | 11 | 20 |
| 2001 | 7 | 14 | 21 |
| 2002 | 7 | 12 | 19 |
| 2003 | 9 | 6 | 15 |
| 2004 | 12 | 9 | 21 |
| 2005 | 5 | 8 | 13 |
| 2006 | 5 | 2 | 7 |
| 2007 | 7 | 2 | 9 |
| 2008 | 2 | 7 | 9 |
| 2009 | 8 | 2 | 10 |
| 2010 | 2 | 5 | 7 |
| 2011 | 3 | 5 | 8 |
| 2012 | 5 | 6 | 11 |
| 2013 | 1 | 4 | 5 |
| 2014 | 4 | 5 | 9 |
| 2015 | 4 | 4 | 8 |
| 2016 | 5 | 9 | 14 |
| 2017 | 1 | 6 | 7 |
| 2018 | 3 | 1 | 4 |
| 2019 | 8 | 5 | 13 |
| 2020 | 6 | 3 | 9 |
| 2021 | 6 | 2 | 8 |
| 2022 | 4 | 2 | 6 |
| 2023 | 0 | 5 | 5 |
| 2024 | 5 | 3 | 8 |
Below are the most recent publications written about "Cyclin-Dependent Kinases" by people in Profiles.
-
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors. Clin Cancer Res. 2024 Dec 02; 30(23):5445-5458.
-
Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer. Nat Cancer. 2024 Dec; 5(12):1885-1901.
-
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13. Cell Rep Med. 2024 Oct 15; 5(10):101758.
-
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial. Clin Cancer Res. 2024 Aug 01; 30(15):3200-3210.
-
An alternative cell cycle coordinates multiciliated cell differentiation. Nature. 2024 Jun; 630(8015):214-221.
-
Mediator kinase inhibition reverses castration resistance of advanced prostate cancer. J Clin Invest. 2024 Mar 28; 134(10).
-
Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations. Clin Genitourin Cancer. 2024 Jun; 22(3):102080.
-
NOTCH localizes to mitochondria through the TBC1D15-FIS1 interaction and is stabilized via blockade of E3 ligase and CDK8 recruitment to reprogram tumor-initiating cells. Exp Mol Med. 2024 Feb; 56(2):461-477.
-
Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-up. Epilepsia. 2024 Jan; 65(1):37-45.
-
In Reply to "Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer". Oncologist. 2023 Nov 02; 28(11):e1129-e1130.